Sicca/Sjögren Syndrome triggered by PD-1/PD-L1 checkpoint inhibitors: data from the International ImmunoCancer Registry (ICIR)

Research output: Contribution to journalArticle

Authors

Colleges, School and Institutes

Abstract

Objective: To analyse the worldwide occurrence of sicca/Sjögren (SjS) syndrome associated with the use of immune checkpoint inhibitors (ICI) in patients with cancer.

Methods: The ImmunoCancer International Registry (ICIR) is a Big Data-Sharing multidisciplinary network composed by 40 specialists in Rheumatology, Internal Medicine, Immunology and Oncology from 18 countries focused on the clinical and basic research of the immune-related adverse events (irAEs) related to cancer immunotherapies. For this study, patients investigating for a clinical suspicion of SjS after being exposed to ICI were included.

Results: We identified 26 patients (11 women and 15 men, with a mean age at diagnosis of 63,57 years). Underlying cancer included lung (n=12), renal (n=7), melanoma (n=4), and other (n=3) neoplasia. Cancer immunotherapies consisted of monotherapy (77%) and combined regimens (23%). In those patients receiving monotherapy, all patients were treated with PD1/PD1-L inhibitors (nivolumab in 9, pembrolizumab in 7 and durvalumab in 4); no cases associated with CTLA-4 inhibitors were identified. The main SjS-related features consisted of dry mouth in 25 (96%) patients, dry eye in 17 (65%), abnormal ocular tests in 10/16 (62%) and abnormal oral diagnostic tests in 12/14 (86%) patients. Minor salivary gland biopsy was carried in 15 patients: histopathological findings consisted of mild chronic sialadenitis in 8 (53%) patients and focal lymphocytic sialadenitis in the remaining 7 (47%); a focus score was measured in 5 of the 6 patients (mean of 1.8, range 1 to 4). Immunological markers included positive ANA in 13/25 (52%), anti-Ro/SS-A in 5/25 (20%), RF in 2/22 (9%), anti-La/SS-B in 2/25 (8%), low C3/C4 levels in 1/17 (6%) and positive cryoglobulins in 1/10 (10%). Classification criteria for SjS were fulfilled by 10 (62%) out of 16 patients in whom the two key classificatory features were carried out. Among the 26 patients, there were only 3 (11%) who presented exclusively sicca syndrome without organ-specific autoimmune manifestations. Therapeutic management included measures directed to treat sicca symptoms and therapies against autoimmune-mediated manifestations (glucocorticoids in 42%, second/third-line therapies in 31%); therapeutic response for systemic features was observed in 8/11 (73%). No patient died due to autoimmune involvement.

Conclusions: Patients with Sjögren syndrome triggered by ICI display a very-specific profile different from that reported in idiopathic primary SjS, including more frequent occurrence in men, a higher mean age, a predominant immunonegative serological profile, and a notable development of organ-specific autoimmune involvement in spite of the poor immunological profile. The close association found between sicca/Sjögren syndrome and primarily PD1 blockade requires further specific investigation.

Details

Original languageEnglish
Pages (from-to)0114-0122
JournalClinical and Experimental Rheumatology
Volume37
Issue number3, Supplement 118
Publication statusPublished - 28 Aug 2019

Keywords

  • Sjögren’s syndrome, immune checkpoint inhibitors, nivolumab, pembrolizumab, durvalumab